Related references
Note: Only part of the references are listed.Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma
Babak Moghimi et al.
NATURE COMMUNICATIONS (2021)
B7-H3x4-1BB bispecific antibody augments antitumor immunity by enhancing terminally differentiated CD8+ tumor-infiltrating lymphocytes
Gihoon You et al.
SCIENCE ADVANCES (2021)
The B7-H3-Targeting Antibody-Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models
Nathan M. Kendsersky et al.
CLINICAL CANCER RESEARCH (2021)
Targeting B7-H3 via chimeric antigen receptor T cells and bispecific killer cell engagers augments antitumor response of cytotoxic lymphocytes
Jie Liu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Tumor B7-H3 expression in diagnostic biopsy specimens and survival in patients with metastatic prostate cancer
Gulanbar Amori et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2021)
Administration of B7-H3 targeted chimeric antigen receptor-T cells induce regression of glioblastoma
Xin Tang et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)
B7-H3 Immune Checkpoint Protein in Human Cancer
Karine Flem-Karlsen et al.
CURRENT MEDICINAL CHEMISTRY (2020)
Interdomain spacing and spatial configuration drive the potency of IgG-[L]-scFv T cell bispecific antibodies
Brian H. Santich et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Efficacy of B7-H3-Redirected BiTE and CAR-T Immunotherapies Against Extranodal Nasal Natural Killer/T Cell Lymphoma
Meijun Zheng et al.
TRANSLATIONAL ONCOLOGY (2020)
Visualizing and interpreting cancer genomics data via the Xena platform
Mary J. Goldman et al.
NATURE BIOTECHNOLOGY (2020)
Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumors
Johanna Theruvath et al.
NATURE MEDICINE (2020)
DS-7300a, a novel B7-H3-targeting antibody-drug conjugate with a novel DNA topoisomerase I inhibitor DXd, exhibits potent anti-tumor effects in nonclinical models
M. Yamato et al.
EUROPEAN JOURNAL OF CANCER (2020)
Preclinical Development of MGC018, a Duocarmycin-based Antibody-drug Conjugate Targeting B7-H3 for Solid Cancer
Juniper A. Scribner et al.
MOLECULAR CANCER THERAPEUTICS (2020)
B7H3-Directed Intraperitoneal Radioimmunotherapy With Radioiodinated Omburtamab for Desmoplastic Small Round Cell Tumor and Other Peritoneal Tumors: Results of a Phase I Study
Shakeel Modak et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Alternative Checkpoints as Targets for Immunotherapy
Ayush Pant et al.
CURRENT ONCOLOGY REPORTS (2020)
B7-H3, a checkpoint molecule, as a target for cancer immunotherapy
Shuo Yang et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2020)
Immunoregulatory protein B7-H3 regulates cancer stem cell enrichment and drug resistance through MVP-mediated MEK activation
Zixing Liu et al.
ONCOGENE (2019)
B7-H3 promotes aerobic glycolysis and chemoresistance in colorectal cancer cells by regulating HK2
Tongguo Shi et al.
CELL DEATH & DISEASE (2019)
CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors
Robbie G. Majzner et al.
CLINICAL CANCER RESEARCH (2019)
B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity
Kimio Yonesaka et al.
CLINICAL CANCER RESEARCH (2018)
T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics
Z. Wu et al.
PHARMACOLOGY & THERAPEUTICS (2018)
B7H3 As a Promoter of Metastasis and Promising Therapeutic Target
Peixin Dong et al.
FRONTIERS IN ONCOLOGY (2018)
A phase 1, open label, dose escalation study of MGD009, a humanized B7-H3 x CD3 DART protein, in combination with MGA012, an anti-PD-1 antibody, in patients with relapsed or refractory B7-H3-expressing tumors.
Sadhna Shankar et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Phase II neoadjuvant and immunologic study of B7-H3 targeting with enoblituzumab in localized intermediate- and high-risk prostate cancer.
Eugene Shenderov et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
The future of immune checkpoint cancer therapy after PD-1 and CTLA-4
Andrew W. Hahn et al.
IMMUNOTHERAPY (2017)
Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function
Young-hee Lee et al.
CELL RESEARCH (2017)
Eradication of Tumors through Simultaneous Ablation of CD276/B7-H3-Positive Tumor Cells and Tumor Vasculature
Steven Seaman et al.
CANCER CELL (2017)
Development of DS-5573a: A novel afucosylated mAb directed at B7-H3 with potent antitumor activity
Akiko Nagase-Zembutsu et al.
CANCER SCIENCE (2016)
B7-H3 Overexpression Predicts Poor Survival of Cancer Patients: A Meta-Analysis
Zhimeng Ye et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2016)
Humanized Affinity-matured Monoclonal Antibody 8H9 Has Potent Antitumor Activity and Binds to FG Loop of Tumor Antigen B7-H3
Mahiuddin Ahmed et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
Differential expression of 2IgB7-H3 and 4IgB7-H3 in cancer cell lines and glioma tissues
Zhenxin Wang et al.
ONCOLOGY LETTERS (2015)
Structure and T Cell Inhibition Properties of B7 Family Member, B7-H3
Vladimir Vigdorovich et al.
STRUCTURE (2013)
Pharmacokinetic, pharmacodynamic and immunogenicity comparability assessment strategies for monoclonal antibodies
Wendy S. Putnam et al.
TRENDS IN BIOTECHNOLOGY (2010)
The contrasting role of B7-H3
Kimberly A. Hofmeyer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Molecular characterization of human 4Ig-B7-H3, a member of the B7 family with four Ig-like domains
P Steinberger et al.
JOURNAL OF IMMUNOLOGY (2004)
Share Paper
